PPP1R3G: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 3G

Target Name: PPP1R3G

NCBI ID: G648791

PPP1R3G

Other Name(s): protein phosphatase 1 regulatory subunit 3G | protein phosphatase 1, regulatory (inhibitor) subunit 3G | Protein phosphatase 1 regulatory subunit 3G | PP13G_HUMAN | putative protein phosphatase 1 regulatory inhibitor subunit 3G

PPP1R3G: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 3G

Protein phosphatase 1 (PP1) is an essential enzyme that regulates various cellular processes, including cell growth, differentiation, and metabolism. The protein encoded by the PPP1 regulatory subunit 3G (PP1R3G) is a key component of PP1, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, targeting PPP1R3G has emerged as a promising strategy for developing new therapeutic approaches.

Drug Targeting Strategies

Drugs that target PPP1R3G directly or indirectly can modulate its activity and potentially lead to therapeutic benefits. Several approaches can be employed to achieve this goal, including:

1. Small molecule inhibitors: Chemical compounds that inhibit the activity of PPP1R3G can be developed as potential drugs. These compounds can be derived from a variety of sources, such as natural products, pharmaceuticals, or synthetics. A variety of screening strategies can be employed to identify promising candidates for further development.
2. mTOR inhibitors: mTOR (mechanistic target of rapamycin) is a key regulator of cell growth and metabolism, and its inhibition can be an effective way to target PPP1R3G. mTOR inhibitors have been shown to be effective in modulating PPP1R3G activity and have been identified as potential therapeutic compounds.
3. inhibitors of the PP1-PP1B complex: The PP1-PP1B complex is a critical regulatory network that regulates the activity of PP1. Disruptions in this complex have been implicated in various diseases, including cancer and neurodegenerative diseases. inhibitors of the PP1-PP1B complex, including PPP1R3G, can be developed as potential drugs.

Biomarker Potential

PP1R3G dysfunction has been associated with various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As such, the quantification of PPP1R3G activity in these conditions can serve as a biomarker for disease assessment. Several approaches can be employed to measure PPP1R3G activity:

1. Biochemical assays: assays such as phosphorylation, cross-linking, or aggregation assays can be employed to measure the activity of PPP1R3G. For instance, the phosphorylation of serine 3G118, a known substrate of PPP1R3G, can be quantified to assess its activity.
2. Cell-based assays: Cell-based assays, such as cell growth assays or live cell imaging, can be employed to measure the impact of drugs or conditions on PPP1R3G activity. For example, the inhibition of PPP1R3G activity can be measured by assessing the growth of cancer cell lines or primary cancer cells.
3. In vitro assays: In vitro assays, such as the formation of covalentcomplexes with other proteins or the determination of protein levels, can be employed to measure the activity of PPP1R3G. For example, the formation of a covalent complex between PPP1R3G and a specific protein can be used as an indicator of its activity.

Conclusion

PP1R3G is a key component of the PP1 regulatory network and its dysfunction has been implicated in numerous diseases. The development of drugs that target PPP1R3G, or its biomarker, has the potential to modulate its activity and improve therapeutic outcomes. Several approaches, including small molecule inhibitors, mTOR inhibitors, and inhibitors of the PP1-PP1B complex, can be employed to achieve this goal. Further research is necessary to fully understand the potential of PPP1R3G as a drug target and biomarker.

Protein Name: Protein Phosphatase 1 Regulatory Subunit 3G

Functions: Glycogen-targeting subunit for protein phosphatase 1 (PP1). Involved in the regulation of hepatic glycogenesis in a manner coupled to the fasting-feeding cycle and distinct from other glycogen-targeting subunits (By similarity)

The "PPP1R3G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R3G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets